 | • レポートコード：B-MOR-08298 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、核酸等温増幅技術（INAAT）の世界市場について調べ、核酸等温増幅技術（INAAT）の世界規模、市場動向、市場環境、技術別（ヘリカーゼ依存増幅（HDA）、切断酵素増幅反応（NEAR）、ループ介在増幅等温増幅（LAMP）、ストランド置換増幅（SDA）、核酸シーケンス増幅（NASBA）、転写介在増幅（TMA）、シングルプライマー等温増幅（SPIA）、その他）分析、用途別（腫瘍、研究、診断、血液検査、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・核酸等温増幅技術（INAAT）の世界市場インサイト ・核酸等温増幅技術（INAAT）の世界市場環境 ・核酸等温増幅技術（INAAT）の世界市場動向 ・核酸等温増幅技術（INAAT）の世界市場規模 ・核酸等温増幅技術（INAAT）の世界市場規模：技術別（ヘリカーゼ依存増幅（HDA）、切断酵素増幅反応（NEAR）、ループ介在増幅等温増幅（LAMP）、ストランド置換増幅（SDA）、核酸シーケンス増幅（NASBA）、転写介在増幅（TMA）、シングルプライマー等温増幅（SPIA）、その他） ・核酸等温増幅技術（INAAT）の世界市場規模：用途別（腫瘍、研究、診断、血液検査、その他） ・核酸等温増幅技術（INAAT）の世界市場：地域別市場規模・分析 ・核酸等温増幅技術（INAAT）の北米市場規模・予測 ・核酸等温増幅技術（INAAT）のアメリカ市場規模・予測 ・核酸等温増幅技術（INAAT）のヨーロッパ市場規模・予測 ・核酸等温増幅技術（INAAT）のアジア市場規模・予測 ・核酸等温増幅技術（INAAT）の日本市場規模・予測 ・核酸等温増幅技術（INAAT）の中国市場規模・予測 ・核酸等温増幅技術（INAAT）のインド市場規模・予測 ・核酸等温増幅技術（INAAT）の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global isothermal nucleic acid amplification technology (INAAT) market is expected to register a CAGR of 10.5%, during the forecast period, (2018-2023). North America dominates the market, due to technological advancement and growing awareness regarding INAAT technique among end-user in the region.
Rise in the Miniaturization of Nucleic Acid based Diagnostics
Miniaturization of biochemical reactions leads to major advantages, where a lower amount of valuable clinical sample and reagents is just one: approximately 1/1000 of the volume used in conventional lab setups has been shown to obtain a similar result. A smaller heat capacity allows for rapid changes in temperature beneficial for the PCR time, as well as a higher parallelism of multiple genetic samples. The benefit of isothermal amplification methods compared to PCR is the constant temperature of amplification. This will result in a high potential for a simple integration in point-of-care devices and a reduction of complexity. With increasing demand of low cost and effective solutions for diagnosis of diseases and increasing demand for point of care applications, these devices are going to witness growth in the future. Also in case of laboratories the sample size required is very small which also helps in reducing the amount of reagents required. Also, the upsurge in the molecular diagnostics market, increasing incidences of chronic diseases and aging population, and increase in the adoption of INAAT over PCR are driving the market growth.
Stringent regulatory framework
In the expanding market for medical devices and therapies, there are stringent regulatory policies in place to ensure the safety of such drugs and devices. These policies are well studied. However, while rigorous regulatory procedures guarantee the quality of the product entering the market, they delay the entry of a drug or device into the market, which could be beneficial to all patients suffering from a disease. Pre-market approval is an FDA process of scientific and regulatory review to evaluate the safety and effectiveness of drugs and devices. There have been procedures by the FDA to heighten the post-market surveillance. The FDA review process takes twice as much as time as European regulatory commissions review bodies. Hence, citizens from countries where the review process is shorter benefit more than countries with longer review processes and stringent regulations. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market. Strict regulatory policies have resulted in a reduction of investment by drug companies in R&D of new products. Also the lack of awareness in new diagnostics technologies may induce users to stick to conventional methods, although this can be addressed with effective marketing
North America to Dominate the Market
North America dominates the Isothermal Nucleic Acid Amplification Technology (INAAT) market, owing to high incidence of chronic diseases, technological advancement in isothermal nucleic acid amplification technology (INAAT), and increasing adoption of INAAT over conventional techniques in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high demand in cost effective and diagnostics, less stringent regulatory scenario, and presence of huge population base.
Key Developments in the Market
• March 2017: Alere Inc. a global leader in rapid diagnostic tests, announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere i Strep A test
Major Players: ALERE, BECTON, DICKINSON & COMPANY, BIOMERIUX, HOLOGICA, LUCIGEN, QUIDEL CORPORATION, NEW ENGLAND BIOLABS, NUGEN, QIAGEN, USTAR BIOTECHNOLOGIES, amongst others.
Reasons to Purchase this Report
• Current and future global isothermal nucleic acid amplification technology outlook, in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Upsurge in the Molecular Diagnosis
6.1.2 Increasing Incidences of Chronic Diseases and Aging Population
6.1.3 Increase in the Adoption of INAAT over PCR
6.1.4 Rise in the Miniaturization of Nucleic Acid Based Diagnosis
6.2 Market Restraints
6.2.1 Threatening Opposition from PCR Technologies
6.2.2 Lack of Awareness of New Diagnostics Technologies
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Technology
7.1.1 Helicase-dependent Amplification (HDA)
7.1.2 Nicking Enzyme Amplification Reaction (NEAR)
7.1.3 Loop-mediated Isothermal Amplification (LAMP)
7.1.4 Strand Displacement Amplification (SDA)
7.1.5 Nucleic Acid Sequence Based Amplification (NASBA)
7.1.6 Transcription Mediated Amplification (TMA)
7.1.7 Single Primer Isothermal Amplification (SPIA)
7.1.8 Others
7.2 By Applications
7.2.1 Oncology
7.2.2 Laboratory Research
7.2.3 Diagnostics
7.2.4 Blood Screening
7.2.5 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest Of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Alere, Inc.
9.2 Becton, Dickinson & Company
9.3 BioHelix
9.4 bioMerieux
9.5 Hologica
9.6 New England Biolabs
9.7 Nugen
9.8 Qiagen
9.9 Quidel Corporation
9.10 List Not Exhaustive
10. Future of the Market